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Abstract
The chemokine CCL22 is abundantly expressed in many
types of cancer and is instrumental for intratumoral recruit-
ment of regulatory T cells (Treg), an important subset of
immunosuppressive and tumor-promoting lymphocytes. In
this study, we offer evidence for a generalized strategy to
blunt Treg activity that can limit immune escape and promote
tumor rejection. Activation of innate immunity with Toll-like
receptor (TLR) or RIG-I–like receptor (RLR) ligands prevented
accumulation of Treg in tumors by blocking their immigra-
tion. Mechanistic investigations indicated that Treg blockade
was a consequence of reduced intratumoral CCL22 levels
caused by type I IFN. Notably, stable expression of CCL22
abrogated the antitumor effects of treatment with RLR or
TLR ligands. Taken together, our ﬁndings argue that type I
IFN blocks the Treg-attracting chemokine CCL22 and thus
helps limit the recruitment of Treg to tumors, a ﬁnding with
implications for cancer immunotherapy. Cancer Res; 75(21);
4483–93. 2015 AACR.
Introduction
The chemokine CCL22 is abundantly expressed in the tissue of
many types of human cancer (1, 2). Its cognate receptor is CCR4, a
transmembrane protein expressed predominantly and constitu-
tively by regulatory T cells (Treg), a subpopulation of immuno-
suppressive T lymphocytes (3). Several studies show that CCL22
leads to the recruitment of Treg to the cancer tissue (1, 2).
Although the role of Treg in cancer remains to be deﬁnitely
established, many reports on human and murine cancers dem-
onstrate a tumor-promoting effect: Treg progressively accumulate
in the blood and lymphoid organs (4) and abundantly inﬁltrate
the tumor tissue itself (5). These tumor-inﬁltrating Treg that
expressCD25and the transcription factor FoxP3 strongly suppress
effector T-cell function ex vivo (1). Indeed, suppression of anti-
cancer immunity ismediatedpredominantly by intratumoral Treg
that suppress CD8 T-cell responses locally at the tumor site (6).
High numbers of tumor-inﬁltrating FoxP3þ Treg correlate with
poor prognosis and have been identiﬁed as a signiﬁcant predictor
of patient death in several types of human cancer (1, 2).
The aim of cancer immunotherapy is to promote antitumor
immunity and to overcome tumor-induced immunosuppression.
Activation of the innate immune system with ligands for pattern
recognition receptors (PRR) or with cytokines such as IFNa can
suppress tumor growth (7, 8). In mice, CpG oligonucleotides
(CpG) that stimulate the Toll-like receptor 9 (TLR9) improve the
efﬁcacy of anticancer vaccines and can also be used as single agent
to reduce tumor size (9, 10). In humans, imiquimod, a synthetic
agonist for TLR7, is used to treat basal cell carcinoma and vulvar
intraepithelial neoplasia, and the cytokines IL2 and IFNa are used
for selected patients with melanoma or renal cell cancer (11, 12).
Furthermore, many TLR activators are currently under investiga-
tion in clinical trials (13).
The impact of PRR-activating ligands on Treg in the tumor-
bearing host is still unclear. It has been shown that PRR activation
can prevent Treg-mediated suppression of T effector cell prolif-
eration in the lymphnode (14, 15), but an effect of PRR activation
on Treg in the tumor tissue has so far not been described. In
particular, it is unknown whether trafﬁcking and tumor inﬁltra-
tion of Treg can be affected by agonists for TLRs and RIG-I–like
helicases.
Materials and Methods
Mice and cell lines
Female BALB/c and C57BL/6 mice were from Harlan-Winkel-
mann. IFNI receptor (IFNAR)-deﬁcient mice on C57BL/6
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background were kindly provided by Dr. Z.Waibler (Paul-Ehrlich
Institute, Langen, Germany).Mice were 5 to 10weeks of age at the
onset of experiments. Animal studies were approved by the local
regulatory agency (Regierung von Oberbayern, Munich, Ger-
many). The human cell lines Jurkat, A-375, A-431, A-549,
CAMA-1, MCF-7, MDA-MB-231, MDA-MB-435s, Panc1, SK-BR-
3, and SW480 and the murine cell lines 4T1, CT26, EL-4 (EG-7),
and B16-F1 were obtained from ATCC, where short tandem
repeat (STR) analysis is used for authentication and were used
within 6 months after resuscitation (ATCC). IMIM-PC1 was
kindly provided by Prof. P. Michl (University of Marburg, Mar-
burg, Germany), Panc02 by Prof. C. Bruns, MethA by Prof.
W. Zimmermann, and mGC8 by Dr. J. N€ockel (all Klinikum der
Universit€atM€unchen,Munich, Germany). Cell lines were authen-
ticated using STR (LGC Standards) and were cultured in complete
DMEMor RPMImedium (PAA Laboratories) and routinely tested
for mycoplasma contamination by MycoAlert Mycoplasma
Detection Kit (LONZA). The CT26-CCL22dox cell line was gen-
erated by lentiviral transduction with a construct containing a
doxycycline (Dox)-inducible CCL22 expression cassette as
described (16). For tumor induction, 0.25  106 (CT26 or
CT26-CCL22dox), 1  106 (B16 and Panc02), and 7.5  106
(EG-7) tumor cells were injected subcutaneously into the ﬂank.
Mice with subcutaneous CT26-CCL22dox tumors were fed with a
normal or 25 mg/kg doxycycline-containing diet (ssniff Spezial-
di€aten GmbH). Tumor size was expressed as the product of the
perpendicular diameters of individual tumors (mm2).
Application of TLR ligands
The fully PTO-modiﬁedCpGoligonucleotide 1826 (50-TCCAT-
GACGTTCCTGACGTT-30) (Coley Pharmaceutical Group) was
injected subcutaneously either peritumorally or in the contralat-
eral ﬂank (100 mg CpG in PBS). EG-7 tumor–bearing mice were
injected with 10 mg CpG complexed with 50 mg of liposomal
transfection reagent DOTAP (Roche). Poly(I:C) (Amersham
Bioscience) was applied intraperitoneally (250 mg). Lipopoly-
saccharide (LPS; Sigma-Aldrich) and resiquimod (R848; Alexis
Biochemicals) were injected subcutaneously into the ﬂank con-
tralaterally to the tumor (20 mg).
Immunohistology and cell counting
To permit the evaluation of highly standardized tissue areas,
mouse tumor samples were bisected perpendicular to the skin at
their widest diameter to obtain cryosections (5 mm) derived from
the tumor center. The following primary antibodies were used: rat
anti-mFoxP3 (eBioscience), rat anti-mCD4 (Biolegend), Syrian
hamster anti-mCD3, and rat anti-mCD8. Cy3 goat anti-Syrian
hamster IgG, biotinylated donkey anti-rat IgG, rhodamin red X
streptavidin, alkaline phosphatase streptavidin (all Jackson
ImmunoResearch) and Alexa-488 or -633 streptavidin (Invitro-
gen) were used as detection reagents. Inﬁltrating cells were
assessed by systematically counting nonoverlapping visual ﬁelds
(high-power ﬁelds, hpf) of the entire tumor section using a
ﬂuorescence microscope equipped with an 40 oil immersion
objective (Carl Zeiss). Necrotic areas and blood vessels were
excluded from evaluation. Counting was performed blinded by
two independent investigators. Immunohistology on human
parafﬁn-embedded sections was performed on biopsy tissue of
breast cancer tissue that was retrieved from the archives of the
Institute of Pathology of the Ludwig-Maximilians-Universit€at
(Munich, Germany). Age of patients ranged from 26 to 80 years.
All patients had been treated surgically between 2004 and 2008 at
the same institution (Department of Obstetrics and Gynecology
Maistrasse, University of Munich, Munich, Germany). Tissue
was stained with the following unconjugated primary antibodies
and the respective isotype control antibodies: rabbit anti-hCCL22
(Peprotech), mouse anti-hCD14 (Novocastra), mouse anti-
hCD68 (Dako), rat anti-hDC-LAMP (Dendritics), mouse anti-
hDC-SIGN (Abcam), and puriﬁed rabbit IgG (Biozol). For detec-
tion, the following secondary antibodies were used: biotinylated
goat anti-rabbit (Vector), Cy2 goat anti-rat, and Alexa Fluor 488
donkey anti-mouse (both Jackson ImmunoResearch). For imag-
ing, a confocal laser scanning microscope (LSM 510, Carl Zeiss)
was used and images were processed using Adobe Photoshop for
adjustment of contrast and size.
Flow cytometry and adoptive T-cell transfer
Tumors weremechanically disrupted, incubated with 1mg/mL
collagenase and 0.05 mg/mL DNAse (both Sigma Aldrich), and
passed through a cell strainer. Single-cell suspensions were resus-
pended in 44%Percoll (Biochrome) and layered over 67%Percoll
prior to centrifugation at 800  g for 30 minutes. Lymphocytes
from the interphasewere stainedwith anti-CD3-PerCP, anti-CD4-
APC, anti-CD103-Fitc (all BD Biosciences) and anti-CCR4-Pe
(Biolegend) followed by intracellular detection of FoxP3 using
either anti-FoxP3-PE or anti-FoxP3-Paciﬁc Blue antibody and
premixed regulatory T-cell staining reagents (Ebioscience). Events
were measured on a FACS Canto II ﬂow cytometer (BD Bio-
sciences) and analyzed with FlowJo software (TreeStar). For
adoptive transfer, single-cell suspensions from the spleen and
lymph nodes of healthy mice were labeled with carboxyﬂuores-
cein diacetate succinimidyl ester (CFSE; Invitrogen) according
to the manufacturer's instructions and injected intravenously
(3 107 cells per recipient mouse) into tumor-bearing recipients
(mean tumor size, 80 mm2).
Cytokine assays of tissue lysates
Tissue homogenates were resuspended in lysis buffer (BioRad
Laboratories) and centrifuged. Total protein concentration was
measured by Bradford assay (BioRad Laboratories). All samples
were diluted to a protein concentration of 10mg/mL, and CXCL12,
CCL21,CCL17, andCCL22concentrationsweremeasuredbyELISA
(R&D Systems). The ﬁnal cytokine concentration was calculated as
nanograms cytokine per gram protein in the respective lysate.
Isolation of tumor-inﬁltrating leukocytes from human ovarian
cancer
Pieces of freshly isolated ovarian cancer specimens resected by
open surgeryweremechanically disrupted, incubatedwith 1mg/mL
collagenase and 0.05 mg/mL DNAse (both Sigma Aldrich),
washed and incubated in PBS containing 2 mmol/L EDTA for
20 minutes. After washing, a second incubation with collagenase
and DNAse was performed before passing the material through a
cell strainer. The obtained single-cell suspension was washed and
used for cell culture or magnetic cell separation. The study was
approved by the local ethics committee.
In vitro TLR stimulation of tumor-inﬁltrating cells and in vitro
AH1 antigen stimulation
Tumor-inﬁltrating murine leukocytes were isolated as described
above for ﬂow cytometry and cells were treated with 5 mg/mL
CpG 1826 (Coley Pharmaceutical Group), 1000 U/mL murine
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IFNa (R&D Systems), 50 ng/mL murine IFNg (PeproTech), or 10
ng/mLmurine IL1b, IL2, IL6, IL10, or IL12 (all PeproTech).Human
tumor cell lines and single-cell suspensions derived from ovarian
cancer specimens were treated with 100 ng/mL human IFNg
(PeproTech), 5 mg/mL CpG2006 (Invivogen), 0.5 mg/mL R848
(Alexis Biochemicals) or transfected with 1,000 ng/mL poly
(I:C) (Invitrogen), 1,000 ng/mL 50-triphosphate RNA (50P-
GCAUGCGACCUCUGUUUGA-30) (synthesiswith theMegashort-
script Kit, Ambion Life Technologies), or with 1,000 ng/mL of a
nonstimulating control RNA (50-AAAAAAAAAAAAAAAAAAA-30)
(CureVac). Prior to cell transfection, poly (I:C) and the RNA was
complexed in 50-mL Opti-MEM medium (Invitrogen) containing
1% Lipofectamine 2000 (Invitrogen). To quantify antigen speci-
ﬁcity, tumor-inﬁltrating T cells were stimulated with AH1 peptide
(2 mmol/L, SPSYVYHQF, Anaspec) for 4 hours in presence of
Brefeldin A (5 mg/mL), ﬁxed and permeabilized (eBioscience
Staining Buffer Set), and incubated with anti-IFNg-PE-Cy7 anti-
body (Biolegend).
Cell sorting
Microbead-based CD11c and CD8 T-cell isolation kits (Miltenyi
Biotec) were used to isolate highly pure dendritic cells (DC; >95%)
and CD8 T cells (>90%) from single-cell suspensions of subcuta-
neous murine tumors. APC-labeled anti-CD11c antibody (Biole-
gend) was used to conﬁrm DC purity via FACS analysis. To isolate
humanCD14þ cells,CD14microbeadswereused (Miltenyi Biotec).
RNA isolation and quantitative PCR analysis of tumor-
inﬁltrating cells
Total RNA was extracted from tumor-inﬁltrating cells using
High Pure RNA Isolation Kit (Qiagen). One microgram of RNA
was converted to cDNA using the Revert Aid First strand cDNA
Synthesis Kit (Fermentas). Quantitative real-time PCR ampliﬁca-
tion was performed with the Light Cycler TaqMan Master (Roche
Diagnostics) on a LightCycler 2.0 instrument (RocheDiagnostics)
together with the Universal Probe Library System (Roche Diag-
nostics). Relative gene expression is shown as a ratio of the
expression level of the gene of interest to that of hypoxanthine
phosphoribosyltransferase (HPRT) RNA. Primers were obtained
from Metabion.
Statistical analysis
All data are presented as mean  SEM and were analyzed as
appropriate by the unpaired Student t test or by ANOVA test using
the Student–Newman–Keuls correction. Correlations were ana-
lyzed 2-tailed by Pearson correlation. Statistical analysis was
performed using GraphPad Prism 5 (GraphPad Software).
Results
Innate immunostimulation reduces tumor inﬁltration by Treg
To investigate the effect of PRR stimulation on tumor inﬁltra-
tion by Treg, we quantiﬁed these cells in CT26 tumors frommice
treated with the TLR9 ligand CpG. Intratumoral Treg and total
CD3þ T cells were visualized by immunoﬂuorescence and
counted according to a highly standardized protocol (see Materi-
als and Methods). A majority of tumors from untreated mice
showed prominent Treg cell inﬁltrations with formation of focal
clusters (analysis of 384 visual ﬁelds from tissue sections of 11
individual tumors; Fig. 1A and B). In mice treated with CpG, Treg
were almost completely absent from the tumors (analysis of 160
visual ﬁelds from 12 tumors). This effect was observed both in
tumors treated with CpG peritumorally and upon CpG injection
distant from the tumor. The decreasewas selective for Treg, as total
inﬁltrating CD3þ T cells were in contrast increased after CpG
treatment (Fig. 1A and B). Selectivity for Treg was also shown
within the CD4þ T-cell population as indicated by a decreased
FoxP3 to CD4 ratio (Supplementary Fig. S1). Using ﬂow cyto-
metry, we conﬁrmed the decrease of intratumoral Treg, demon-
strated by a reduction in FoxP3þ cells per gram tumor tissue and a
proportional decrease within the CD3 and CD4 T cells (Fig. 1C;
Supplementary Fig. S1). Four days after a single CpG injection, the
absolute number of intratumoral Tregwas still strongly decreased.
Treg numbers returned to the level of untreated mice 8 days after
one CpG injection, although the Treg to CD8 ratio remained
strongly decreased (Supplementary Fig. S1C). Decreased Treg cell
inﬁltration was not limited to the CT26 model, as a reduction in
tumor-inﬁltrating Treg was observed upon CpG treatment in two
additional tumor models in mice of different genetic background
(Supplementary Fig. S2). To test whether suppression of intratu-
moral Treg inﬁltration canbemediatedbyactivationof other PRR,
we injectedmice with theMDA-5 and TLR3 ligand poly(I:C) (17),
the TLR7 ligand R848, and the TLR4 ligand LPS. Inﬁltrating
FoxP3þ and CD3þ cells were quantiﬁed in 750 visual ﬁelds
of 23 tumors. As seen after CpG application, treatment with
poly(I:C) and R848 led to a striking reduction in tumor-
inﬁltrating FoxP3þ cells with a strong decrease of the FoxP3
to CD3 ratio (Fig. 1D). No signiﬁcant reduction was seen upon
treatment with LPS, which may be due to the fact that LPS also
induces Treg proliferation (18). In conclusion, PRR activation
with CpG, poly(I:C), or R848 clearly and selectively decreases
the number of Treg within tumor tissues.
Innate immune activation inhibits the migration of regulatory
T cells into the tumor
To examine whether the decreased numbers of intratumoral
Treg result from a reduced migration of FoxP3þ cells into the
tumor, we analyzed the trafﬁcking of adoptively transferred Treg
in tumor-bearing mice that had been treated with CpG. Mice
bearing established CT26 tumors received one injection of CpG.
Twenty-four hours later, CFSE-labeled cells from the spleen and
lymph nodes of healthy donor mice were transferred intraven-
ously. Tumors were resected 18 hours after transfer and CFSEþ T
cells were analyzed by ﬂow cytometry (Fig. 2A). Strikingly, in the
tumors of CpG-treated animals, the fraction of transferred Treg
within intratumoral CFSEþ CD3þ T cells was reduced on average
almost 4-fold compared with untreated mice (Fig. 2A and B). In
contrast, no difference in the proportion of transferred Treg was
observed in the spleen. Within the intratumoral CD4 T cells, the
proportion of transferred FoxP3þ Treg was also reduced, whereas
no decrease was observed for FoxP3neg T effector cells (Fig. 2C),
indicating a speciﬁc inhibition of Treg migration. In conclu-
sion, these ﬁndings demonstrate that CpG suppresses the migra-
tion of FoxP3þ Treg into the tumor.
Innate immune activation suppresses tumor-associated CCL22
in mice and humans
The migration and retention of Treg in peripheral tissues is
mediated by the interaction of speciﬁc integrins and chemokine
receptors with their respective ligands (19). To characterize the
molecularmechanisms responsible for the decrease in Tregmigra-
tion into the tumor upon treatmentwith TLR ligands, we analyzed
the expression of several Treg-related chemokines and chemokine
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Figure 1.
Ligands for TLR and RLR prevent tumor inﬁltration by Treg. Mice bearing CT26 tumors with an average size of 60 mm2 were treated three times at 2-day intervals
with CpG, either peritumorally (p.t., n ¼ 8) or contralaterally (c.l., n ¼ 4), poly(I:C) (n ¼ 6), R848 (n ¼ 6), or LPS (n ¼ 5) or remained untreated (n ¼ 18). Two
days after the last injection, tumors were prepared for histology and stained for FoxP3 and CD3 or analyzed by ﬂow cytometry. A, representative tissue areas of
untreated and CpG-treated CT26 tumors, FoxP3þ (green), and CD3þ (red). B, inﬁltrating FoxP3þ and CD3þ cells were counted in each tumor sample as described in
Materials and Methods. Each data point represents the number of positive cells in one visual ﬁeld (0.25 mm2). Each dataset (vertically aligned dots) represents
a tumor from an individual mouse. Numbers at the bottom of each dataset indicate the number of visual ﬁelds counted per tumor. Bars indicate the mean cell
count per visual ﬁeld in one tumor. The ratio of FoxP3þ to CD3þ cells is indicated (histogram). C, the absolute number of tumor-inﬁltrating CD4þ FoxP3þ Treg per gram
tumor and the proportion of FoxP3þ cells within tumor-inﬁltrating CD3þ T cells were determined by ﬂow cytometry. Data for one representative mouse per
group and average of all mice per group (n ¼ 7) are shown. D, CT26 tumors from poly(I:C)-, R848-, and LPS-treated mice were analyzed for FoxP3þ and CD3þ cell
inﬁltration by immunohistology. Data are represented as in B. Error bars, SEM. P values were calculated relative to untreated mice ( , P < 0.05;  , P < 0.01).
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receptors after TLR stimulation of tumor-bearing mice. Two
receptors expressed on Treg are critically involved in the recruit-
ment of these cells: the chemokine receptor CCR4 (3) and
the integrin CD103 thatmediates retention of Treg within periph-
eral tissues (20). Treatment of tumor-bearing mice with CpG did
not modify the expression of CCR4 or CD103 on FoxP3þ cells
(Fig. 3A). Several chemokines such as CCL5, CCL17, CCL21,
CCL22, and CXCL12 have been described to mediate homing
of Treg in different circumstances (19, 21–23). In addition, the
chemokine CCL22 has been associated with homing of Treg to
malignant tumors (1, 19). We analyzed intratumoral levels of
all these chemokines in CT26 tumors of CpG-treated mice by
ELISA. Strikingly, we found a strong suppression of CCL22
levels in the tumor tissue upon treatment with the TLR ligand
(Fig. 3B). A decrease was also observed for CCL17, although
this chemokine was expressed only at very low levels. No
suppression was seen for CCL5, CCL21, or CXCL12 (Fig.
3B). Substantial intratumoral levels of CCL22 were observed
in three other subcutaneous murine tumor models, and treat-
ment with CpG decreased intratumoral CCL22 in all three
models (Fig. 3C). Furthermore, suppression of intratumoral
CCL22 was also seen upon injection of poly(I:C), R848, or
LPS, showing that this also results from activation of other
PRR (Fig. 3D).
Interestingly, we observed a linear correlation between intra-
tumoral CCL22 and the number of inﬁltrating FoxP3þ cells
(Supplementary Fig. S3). To examine whether the reduction of
intratumoral Treg by TLR ligands is due to suppression of CCL22,
we established aCT26 tumor cell linewith inducible expression of
CCL22 (CT26-CCL22dox). In this model, exposure of the tumor
cells to doxycycline induces secretion of CCL22 (Supplementary
Fig. S4A). When CT26-CCL22dox cells were implanted subcuta-
neously inmice, addition of doxycycline to the diet of the animals
led to increased intratumoral CCL22 production and enhanced
inﬁltration of tumors with Treg (Supplementary Fig. S4B). Doxy-
cycline-dependent induction of CCL22 expression in these
tumors was used to prevent the suppression of intratumoral
CCL22 by TLR ligands. Indeed, no suppression of CCL22 was
observed upon treatmentwithCpG inmice bearing subcutaneous
CT26-CCL22dox tumors that received doxycycline (Fig. 3E, left).
Strikingly, in this groupofmice, no reduction of intratumoral Treg
was observed, demonstrating that suppression ofCCL22 is indeed
responsible for the inhibition of Treg migration upon TLR stim-
ulation (Fig. 3E, right).
We next examined whether suppression of tumor-associated
CCL22 is also aphenomenon that canbe observed in humans.We
prepared single-cell suspensions from freshhumanovarian cancer
samples and incubated these with ligands for different PRR. High
levels of CCL22 were detected in the untreated culture super-
natants, whereas application of R848, poly(I:C) and triphosphate
RNA as ligand for RIG-I suppressed CCL22 (Fig. 3F). Interestingly,
CCL22 suppression in the human tumor supernatants was absent
upon stimulation with CpG (Fig. 3F). This is probably due to the
more restricted expression pattern of the receptor for CpG, TLR9,
in humans. Thus, PRR activation suppresses cancer-associated
CCL22 in both mice and humans.
Dendritic cells andmacrophages produceCCL22 inmurine and
human tumors
To elucidate the mechanisms of CCL22 suppression, we next
aimed to identify the source of intratumoral CCL22. Culture
supernatants of seven different murine tumor cell lines, including
the CT26, B16, EG-7, and Panc02 cells, were uniformly negative
for CCL22, indicating that the tumor cells themselves do not
produce the chemokine (Fig. 4A). As in secondary lymphatic
organs ofmice CD11cþ dendritic cells are the producers of CCL22
(24), we hypothesized that these cells could also be responsible
for the production of CCL22 in tumors. To test this hypothesis, we
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TLR stimulation suppresses intratumoral CCL22 in mice and humans. A and B, CT26 tumor–bearingmice were treated with CpG as described in Fig. 1 (n¼ 6mice per
group). A, expression of CD103 and CCR4 on CD4þFoxP3þ splenic Treg was assessed by ﬂow cytometry 2 days after the last injection. B, homogenates of the
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isolated CD11cþ cells from subcutaneous tumors. Expression of
CCL22 was observed almost exclusively in the CD11c-positive
fraction, indicating that tumor-inﬁltrating dendritic cells are the
source of intratumoral CCL22 in mice (Fig. 4B). As a previous
study (25) suggested apotential role forCD8þ intratumoral T cells
as source of CCL22, we also isolated CD8 T cells from the tumors
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Dendritic cells and macrophages produce CCL22 in murine and human tumors. A, culture supernatants of murine tumor cell lines and bone marrow–derived
dendritic cells (BM-DC, used as positive control) were analyzed for secretion of CCL22 by ELISA. B, CD11cþ cells and CD8þ T cells were isolated from subcutaneous
CT26 and B16 tumors, and CCL22 mRNA levels were quantiﬁed by qRT-PCR. C, CCL22 levels in the culture supernatants of different human tumor cell lines
were measured by ELISA. D, representative examples of human breast cancer tissue sections were stained for CCL22 (brown cells). E, CD14þ cells isolated
from single-cell suspensions of freshly dissected ovarian cancer specimens were cultured for 3 days (n ¼ 4 patients). CCL22 was then measured in the culture
supernatants. F, breast cancer tissues were prepared for histology and stained for CCL22 (red) and CD14, CD68, DC-LAMP, DC-SIGN (green), or with
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but could not detect CCL22 expression in this fraction (Fig. 4B).
We further measured CCL22 levels in the supernatant of several
human cancer cell lines. No detectable CCL22 levels were seen in
the majority of samples, except for two breast cancer and one
melanoma cell line that secreted CCL22 (Fig. 4C). Because CCL22
secretion has been reported upon stimulationwith IFNg in several
breast cancer cell lines (26), we stimulated all human cell lines
with IFNg . This indeed enhanced the chemokine production of
the CCL22-secreting breast cancer andmelanoma cells (CAMA-1,
MCF-7, and melanoma A431), but CCL22 secretion remained
undetectable in all other cell lines tested (Supplementary Fig. S5).
As CCL22 was not secreted by the majority of human cancer cells
tested, it appeared likely that, as in mice, tumor-inﬁltrating
immune cells were responsible for the production of intratu-
moral CCL22. We performed immunohistology of ovarian and
breast cancer tissues and found CCL22 to be expressed by cells
with macrophage-like morphology (Fig. 4D). We therefore
isolated CD14-positive cells from single-cell suspensions of
fresh ovarian cancer specimens, cultured the cells for 3 days,
and determined CCL22 levels in the supernatants. CCL22
production was restricted to the CD14-positive fraction, dem-
onstrating that these cells represent the main source of CCL22
in these human tumors (Fig. 4E). Double immunoﬂuorescent
imaging revealed colocalization of CCL22 with CD14 and
CD68, conﬁrming the expression by macrophages (Fig. 4F).
Interestingly, some mature dendritic cells, characterized by
staining of DC-LAMP, were also positive for CCL22, whereas
no colocalization was shown for DC-SIGN, a marker for more
immature dendritic cells (Fig. 4F). In conclusion, intratumoral
CCL22 is secreted by inﬁltrating dendritic cells and macro-
phages rather than by the tumor cells themselves.
Suppression of intratumoral CCL22 is mediated by type I IFN
To investigate the mechanism of CCL22 suppression, we mea-
sured the secretion of this chemokine by tumor-inﬁltrating
immune cells under different culture conditions. First, we found
that culture supernatants from TLR-stimulated splenocytes (the
TLR ligand itself was removed by washing 2 hours after stimula-
tion) suppressed CCL22 secretion by freshly isolated tumor-
inﬁltrating immune cells, suggesting that a secreted factor
was responsible for CCL22 suppression (data not shown). To
identify this factor, we incubated the tumor-inﬁltrating immune
cells with a set of recombinant cytokines that are typically
released upon innate immune activation (27). A minor
decrease of CCL22 was seen upon addition of IL10 and IFNg
and no change or even an increase occurred with IL1, IL2, IL6,
and IL12 (data not shown). In contrast, potent suppression of
CCL22 was seen upon treatment of the tumor-inﬁltrating cells
fromCT26, B16, and Panc02 tumors with IFNa (Fig. 5A). CCL22
secretion was also suppressed by IFNa in isolated tumor-derived
CD11cþ cells, indicating that dendritic cells are directly targeted
by IFNa (Fig. 5B). To evaluate the contribution of IFNa to
the suppression of CCL22 by innate immune activation, we
induced tumors in interferon receptor–deﬁcient mice (IFNAR)
and treated these animals by PRR stimulation. Strikingly, no
suppression of intratumoral CCL22 and tumor growth was seen
in IFNAR mice (Fig. 5C; Supplementary Fig. S6A), demonstrat-
ing that type I IFN is a key mediator in the process of CCL22
suppression. Treatment of tumors with recombinant IFNa
tended to reduce intratumoral CCL22 and Treg numbers but
did not signiﬁcantly suppress them, indicating a higher efﬁcacy
of PRR-induced IFNa (Supplementary Fig. S6B).
CCL22 suppression is required for effective antitumor
immunotherapy
Theoutcomeof antitumor treatmentwithCpG is dependent on
an effective CD8þ T-cell response (ref. 9 and Supplementary Fig.
S7). We examined the contribution of the suppression of intra-
tumoral CCL22 to this therapeutic effect of CpG. We treatedmice
bearing CT26-CCL22dox tumors with CpG and simultaneously
prevented suppression of CCL22 by feeding with doxycycline. As
expected, in the absence of doxycycline, a clear suppression of
tumor growth was observed in the animals receiving CpG treat-
ment (Fig. 6). In contrast, CpG treatment did not signiﬁcantly
block tumor growth when intratumoral CCL22 secretion was
maintained by doxycycline administration. Thus, we demonstrate
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Suppression of intratumoral CCL22 is mediated by type I IFN. A, tumor-inﬁltrating cells from subcutaneous CT26, B16, and Panc02 tumors. B, CD11c positively sorted
single-cell suspensions from Panc02 tumors were treated with IFNa or remained untreated. After incubation for 3 days, CCL22 levels in the supernatants
were determined by ELISA. C, subcutaneous B16 tumorswere induced in C57BL/6 (n¼ 10) or IFNARmice (n¼ 10). At day 21 after tumor induction, both groupswere
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that suppression of CCL22 is necessary for the therapeutic efﬁcacy
of TLR ligands.
Discussion
Tumor-inﬁltrating Treg inhibit antitumor immunity (6) and
are associated with poor prognosis in several types of human
cancer (1, 2). In the present study, we show that stimulation of
innate immunity through TLRs and RIG-I–like helicases strong-
ly reduces the absolute number of intratumoral FoxP3þ Treg in
several mouse tumor models in a highly selective manner.
Indeed, the number of FoxP3-negative effector CD8þ T cells
within the tumor was even increased. This is in accordance with
previous reports showing higher proportions of T effector cells
upon treatment with CpG (28). The TLR7 agonist imiquimod
increased the T effector cell to Treg ratio in human squamous
cell cancer but did not alter the proportion of antigen-speciﬁc T
effector and Treg cells in the lymph node in a murine antitumor
vaccine model (29, 30). Interestingly, a suppression of Treg
inﬁltration upon treatment with CpG has been reported in a
model of leishmania infection of the skin: TLR stimulation of
the animals reduced the number of FoxP3þ cells in the infected
skin and thus led to clearance of the pathogen (31). We show
here that suppression of intratumoral Treg by TLR agonists
results from a blockade of Treg immigration into the tumor.
This is to our knowledge the ﬁrst report demonstrating a direct
inhibition of Treg migration upon innate immune activation.
Taken together with the observation that TLR stimulation
suppresses Treg inﬁltration in leishmania infection, these ﬁnd-
ings suggest that activation of the innate immune system
through TLRs may generally prevent Treg migration to sites of
inﬂammation. The local reduction of Treg in response to
microbial patterns could thus permit an efﬁcient response
against pathogens within the affected tissues.
It was previously demonstrated that ligands for PRR and
cytokines such as IFNa affect immunosuppression exerted by
Treg. For instance, activation of TLR7 and TLR9 on dendritic cells
renders T effector cells refractory to Treg suppression, whereas
stimulation with IFNa or ligands for TLR2 and MDA-5 expressed
by Treg can directly inhibit their suppressive function or suppress
their proliferation (15, 32–34). We describe here the blockade of
Treg migration as a novel mechanism of action in the process of
innate immune activation by ligands for PRR. We further show
that inhibition of Treg migration indeed contributes to tumor
regression. The efﬁcacy of modulating Treg and T effector cell
activity for immune activation against cancer has recently been
highlighted by the success of the CTLA-4 blocking antibody
ipilimumab (35). Furthermore, blockade of the Treg-associated
receptor CCR4 by a small molecule enhanced tumor immunity
(36). Thus, inhibition of Treg migration represents an interesting
future concept of anticancer immunotherapy.
An analysis of several Treg-associated chemokines and homing
receptors during immune activation revealed a potent suppression
of intratumoral levels of CCL22, a chemokine that is crucial for the
recruitment of Treg to tumors: In mice, CCL22-mediated Treg
migration has been shown in a model of lung cancer (37), and
in humans, high levels of intratumoral CCL22 have been observed
inmany types of cancer (1, 2, 26, 38). The cellular source of CCL22
in the tumor tissue is however still unclear.We showhere that with
the exceptionof some typesofbreast cancer andmelanoma,CCL22
is secreted not by the tumor cells or by tumor-inﬁltrating T cells as
previously reported (25) but by tumor-inﬁltrating dendritic cells
andmacrophages. Interestingly, it has been generally assumed that
CCL22 secretion is enhanced rather than suppressed upon TLR
stimulation (39, 40). This assumption is however based on obser-
vationsmade using dendritic cells differentiated in vitro (39, 40), in
which we also observed enhanced CCL22 secretion upon TLR
stimulation (data not shown). In primary cells isolated from
murine or human tumors, however, we clearly show that CCL22
secretion by dendritic cells and macrophages is suppressed upon
stimulation with CpG and other activators of innate immunity.
Suppression of CCL22 upon PRR stimulation was dependent
on type I IFN. The concept of CCL22 suppression by type I IFN is
supported by previous reports where IFNa-containing combina-
tions were used: CCL22 was reduced in CD3-stimulated T cells
upon treatment with IL12 and IFNa (41), in peripheral human
blood-derived dendritic cells upon incubation with an IFNa-
containing maturation cocktail (42) and in tumor cell cultures
through aCOX1 inhibitor and IFNa (43).We clearly demonstrate
here that IFNa as a single agent directly suppresses CCL22
secretion of tumor-inﬁltrating immune cells. Although TLR-
induced CCL22 suppression critically depends on IFNa, treat-
ment with recombinant IFNa alone was not as efﬁcient as TLR
ligands for CCL22 suppression, a phenomenon that could be
explained by the different pharmacokinetics of these agents. A
major contribution of IFNa to the therapeutic efﬁcacy of TLR
ligands such as CpGor poly(I:C) was shownpreviously and could
be conﬁrmed here (refs. 44, 45 and Supplementary Fig. S6). We
now demonstrate that the type I IFN–dependent CCL22 suppres-
sion contributes to the anticancer effect of innate immune acti-
vation. Indeed, cancer therapy with IFNa is established for mel-
anoma and can also be used for other types of human cancer (8).
Our ﬁndings uncover CCL22 suppression as a so far unknown
mechanism of action of anticancer therapy with IFNa. This has
important therapeutic implications as patients with high intra-
tumoral CCL22may derive a higher beneﬁt from IFNa treatment.
It will be interesting to investigate intratumoral CCL22 as a
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predictive biomarker for IFN treatment. In summary, our ﬁndings
identify inhibition of Treg migration by CCL22 suppression as a
so far unknown mechanism of innate immune activation with
important implications for cancer therapy.
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